Analysts Set Evolus, Inc. (NASDAQ:EOLS) Target Price at $14.50

Evolus, Inc. (NASDAQ:EOLS) has received a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $14.50.

EOLS has been the subject of several research analyst reports. BTIG Research restated a “buy” rating and set a $13.00 price target on shares of Evolus in a research note on Wednesday, June 17th. HC Wainwright reiterated a “buy” rating and issued a $13.00 price objective on shares of Evolus in a research note on Tuesday, August 25th. Wall Street Zen raised Evolus from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Finally, Weiss Ratings raised shares of Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 15th.

Evolus Stock Performance

EOLS opened at $8.88 on Monday. Evolus has a fifty-two week low of $3.86 and a fifty-two week high of $9.12. The firm has a 50-day moving average of $7.04 and a 200 day moving average of $5.93. The firm has a market cap of $586.52 million, a P/E ratio of -17.08 and a beta of 1.35.

Institutional Investors Weigh In On Evolus

Several hedge funds have recently bought and sold shares of EOLS. Rhumbline Advisers lifted its position in Evolus by 2.0% in the second quarter. Rhumbline Advisers now owns 85,093 shares of the company’s stock valued at $784,000 after purchasing an additional 1,657 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Evolus by 5.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,289 shares of the company’s stock worth $400,000 after buying an additional 1,838 shares during the period. Invesco Ltd. increased its stake in shares of Evolus by 7.5% in the second quarter. Invesco Ltd. now owns 34,283 shares of the company’s stock worth $316,000 after buying an additional 2,383 shares during the period. California State Teachers Retirement System raised its holdings in Evolus by 79.9% during the 2nd quarter. California State Teachers Retirement System now owns 5,455 shares of the company’s stock valued at $38,000 after buying an additional 2,423 shares during the last quarter. Finally, Larson Financial Group LLC raised its holdings in Evolus by 136.6% during the 4th quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock valued at $33,000 after buying an additional 2,837 shares during the last quarter. 90.69% of the stock is currently owned by institutional investors.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.